Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals — Investor Presentation (January 2015)

30 slides from Sucampo Pharmaceuticals's investor presentation, Jan 12, 2015

  1. Slide 1: Sucampo Pharmaceuticals, Inc. Management Team

    Sucatipe Pharmaceuticals, Inc. Peter Greenleaf Chief Executive Officer ‘Sucampo Management Team e Fee inmritio

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains “forward-looking statements" as that term is defined in the Private Securities igation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ mate

  3. Slide 3: Investment Highlights

    Investment Highlights Global biopharmaceutical company founded in 1996, which has two approved products: = AMITIZA® in gastroenterology = RESCULA® in ophthalmology Recently signed partnerships for AMITIZA provide significant long-term revenues Pipeline with mid-to-late stage assets in development Lo

  4. Slide 4: Executed in Three Areas

    Executed in Three Focus our efforts ¥ Strengthen our overall capabilities ¥ Secure AMITIZA franchise and drive v Advance AMITIZA life cycle management ¥ Optimize our investment in prostone = Diversify our scientific y growth programs footprint in strategically over ign the = Enrich the pipeline with

  5. Slide 5: Expanded Management Experience

    Histogenics lal ohmen.fofinen Medrine AstraZeneca € centocor BistoLMyers Squibb Md] Atabex Metinmine Zyngenia “Peter ie D Alcon ESBATech Expanded Management #CYTOS micr@met Cooley 0 novartis Pilea = Experience Gamay il idl axeer <P Cp mencx Lingle) SANOFI Development and "Stanley Miele Commercializa

  6. Slide 6: Two FDA-Approved Products

    Two FDA-Approved Products Therapeutic Area: Gastroenterology = Most expansive label in constipation market wee ami ZEEE Mosttexpertenced products om prescriptions in'oxyenrs lubiprostone + Welltolerated product with well-established safety profile = Therapeutic Area: Ophthalmology = Approved in the

  7. Slide 7: Growth Strategy

    Growth Strategy ‘Continue to "Grow Sales New Agreements: arket Expansion Global Expansion — | Lifecycle Management — | New Patient Population and Formulations — “IMS Health Data Nov 201: US. Rr’s* Q314US.NetSales Q3 14 Japan Sales = Extended U.S. and Canadian Collaboration + Takeda will split wth Su

  8. Slide 8: Linaclotide

    Linaclotide Benober spans ceteatneevan 7] Siruartiavaives Other Sorbitol, mineral ail Branded Generic Osmi Prep, PEG preps Fleet Enemas ——_ : AMITIZA Laxatives emi Prep, PEG props 0% Sort miner (BcLax, Pre-xray oul 0% $6520 Miratox, PEGS Dulcolax) y Bulk Fiber (Cruel ent ner Benefiber) symptoms 85 a

  9. Slide 9: Global AMITIZA Approvals and Regulatory Filings

    Global AMITIZA Approvals and Regulatory Filings MRP in select E.U. countries cic UK. CIC (2012) OIC under add’ Canada CIC and OIC review ‘started 10/31/14) filed * Switzerland CIC (2009) OIC (2014) Us. CIc (2006) IBS-C (2008) OIC (2013) Takeda has rights to all markets except Japan (Abbott) and Chin

  10. Slide 10: Science & Pipeline

    ipo Science-& Pipeline $ sucamMPo 0 ‘The Science of Innovation

  11. Slide 11: At-A-Glance: Sucampo Pipeline

    At-A-Glance: Sucampo Pipeline CLINICAL FOCUS | STAGE OF CLINICAL DEVELOPMENT [LEAD coupounos [eraser] PHASE 2 | PHASE 3 REGULATORY [APPROVAL airow | nae a Cobiprostone ~ Oral Mucositis fetes Pasa 2H 2018 2H 2019 Cobiprostone - NERD wane | swans 0 r20 Now Formation Unoprostone Isopropyl ~ RP MICOMPLE

  12. Slide 12: Goals and Milestones

    als and Milestones $ sucamMPo 2 ‘The Science of Innovation

  13. Slide 13: Stock Price, Market Cap and Financial Highlights

    Stock Price (01-09-15), 52-Week Range $13.74; $5.80~ $1490 Shares Outstanding (01-09-15) 442M (1 class of common stock) Enterprise Value (01-09-15) Dally Volume (90-day average) 210,860 Market Capitalization (01-09-15) $607.3M $549.0M —____inanciattightights fora 2014 Cash & Equivalents $106.44 Note

  14. Slide 14: Upcoming Milestones

    Upcoming Milestones Expected Ting Global partnership agreement for AMITIZA v Updated on AMITIZA alternate formulation and PFC development q Filed AMITIZA (CIC and OIG) for approval in Canada q Initiated MRP to secure approval for AMITIZA (CIC) in additional European markets q Decision made on ion ch

  15. Slide 15: We Have Executed Key Components of Our Strategy

    We Have Executed Key Components of Our Strategy, Focus efforts and strengthen overall capabilities v Team ¥ Development capability Secure and grow AMITIZA revenues v Efforts to ensure consistent and sustainable growth ¥ Global partnerships v Patent litigation resolution Optimize investment in curren

  16. Slide 16: $ SUCAMPO

    e ‘6 $ SUCAMPO ‘The Science of Innovation

  17. Slide 17: $ sucamPo

    e $ sucamPo ‘The Science of Innovation

  18. Slide 18: Lubiprostone Pediatric Functional Constipation

    Lesions Pediatric Functional Constipation What is this disease state? = Constipation is one of the most common gastrointestinal complains in children. The prevalence of PFC worldwide is estimated to be between be anywhere between 4-37%. Only 50-70% of children with functional constipation demonstrat

  19. Slide 19: Cobiprostone in Oral Mucositis (OM)

    Cobiprostone in Oral Mucositis (OM) What is this disease state? « OMis a debilitating side effect of radiation therapy and chemotherapy, causing large ulcers inside an individuals mouth. More than 89% of patients with head and neck cancer (HNC) receiving radio/chemotherapy develop OM. There are roug

  20. Slide 20: Cobiprostone for Non Erosive Reflux Disease

    ‘ostone for Non Erosive Reflux Disease What is this disease state? « NERD is a subtype of GERD (gastro-esophagael reflux disease) and is a condition where the reflux of gastric content causes painful complications that are masked by normal- appearing mucosa. It is estimated that between 27-37M peopl

  21. Slide 21: Ion Channel Activator Lumbar Spinal Stenosis

    PO lon Channel Activator Lumbar Spinal Stenosis (LSS) What is this disease state? « LSS is a degenerative disease of the lumbar spine caused by a narrowing of the spinal canal. LSS causes diminished blood flow, numbness and muscle weakness in the lower extremities, as well as increased pain while wa

  22. Slide 22: Unoprostone Isopropyl for Retinitis Pigmentosa

    Unoumestone Isopropyl for Retinitis Pigmentosa What is this disease state? = RP is typically diagnosed in adolescents and young adults, and is a progressive disorder. RP is caused by gene mutations (variations) inherited from one or both parents. RP typically begins with degeneration of rods, follow

  23. Slide 23: AMITIZA: Intellectual Property

    AMITIZA: Intellectual Property AMITIZA has a robust U.S. patent estate = 16 patents in Orange Book = Latest patents expire in 2027 Recently settled Par litigation = Sucampo and RTU will grant Par a non-exclusive license to market Par's generic version in the U.S. beginning January 1, 2021, or earlie

  24. Slide 24: AMITIZA Collaborations: Extended and Global

    AMITIZA Collaborations: Extended and Global Original U.S. and Canadian Collaboration * Takeda promotes, markets, and sells AMITIZA in U.S. and Canada * Product royalty agreement: tiered royalty rate of 18%-26% of annual net sales = Takeda will no longer reimburse Sucampo for the product details made

  25. Slide 25: Our Heritage

    ng Heritage 1996 Dr. Sachiko Kuno and Dr. Ueno found R-Tech Ueno (USA), Ine later to become Sucampo 2008 2009 2013 AMITIZA AMITIZA AMITIZA approved approved approved for frlBS-C for CICin OIC inthe inthe U.S. Switzerland eee launched RESCULA in the US. $ sucAMPo 2 ‘The Science of Innovation

  26. Slide 26: AMITIZA: Product Profile and Differentiation

    AMITIZA: Product Profile and Differentiation AMITIZA’s MOA Most expansive label in constipation market lubiprostone Most experienced product: 9M prescriptions in 8+ years _ Well-tolerated product with well- hare eo] established safety profile = 8+ years’ postmarketing = No black box warning (contras

  27. Slide 27: Constipation Market Overview

    Constipation Market Overview Chronic Idiopathic Constipation (CIC) « Affects approximately 14% to 16% of adult population globally = 33M in U.S., 41M in E.U. 5, 15M in Japan (CC) = Accounts for 92K hospitalizations/year in U.S. = Severe constipation is associated with increased CV risk in women Irri

  28. Slide 28: Takeda is a Global GI Leader

    Takeda is a Global GI leader a PANTOPRAZOLE ag wastes DEXILANT amitiza dexlansoprazole lubiprostone p—— Launched in 2014 Si Entyvio. vedolizumab Pipeline Vonoprazan (Acid Disorders / Japan) Filing TAK-114 (UC) Phase II ENTYVIO Subcutaneous, Phase | SUCAMPO a Takeda Pharmaceutical Company Limited ) T

  29. Slide 29: RESCULA

    RESCULA Glaucoma is the second leading cause of bilateral blindness worldwide « Expected to affect an estimated 79.6M people worldwide by 2020 = Reduction in intra-ocular pressure (IOP) is currently the only modifiable risk factor for patients with glaucoma and ocular hypertension RESCULA targets IO

  30. Slide 30: References

    References 4. IMS, NPA Data 2 Sucampo data on file 3, Internal Research $ sucamPo 20 ‘The Science of Innovation

Sucampo Pharmaceuticals — Investor Presentation (January 2015) on 6ix